SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage
biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today
announced that Tassos Gianakakos, Chief Executive Officer, will present at the 2018 Wedbush Pacgrow Healthcare
Conference on Tuesday, August 14, 2018, at 10:55 a.m. ET in New York, NY.
A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website
at http://investors.myokardia.com. A replay of the webcast will be available on
the MyoKardia website for 90 days following the conference.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover,
develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s
initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically driven forms of heart failure that
result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a
pipeline of therapeutic programs for the chronic treatment of two of the most prevalent forms of heritable cardiomyopathy –
hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten
(formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin intended to reduce hypercontractility. Mavacamten
is being studied in a pivotal Phase 3 clinical trial, known as EXPLORER-HCM, in patients with symptomatic, obstructive HCM.
MyoKardia is also developing mavacamten in a second indication, non-obstructive HCM, in the Phase 2 MAVERICK-HCM clinical
trial. MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM
patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1b study in DCM patients.
A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center,
international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia
helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold
and innovative science.
Contacts:
Michelle Corral
Corporate Communications & Investor Relations
MyoKardia, Inc.
650-351-4690
mcorral@myokardia.com
Hannah Deresiewicz (investors)
Stern Investor Relations, Inc.
212-362-1200
hannahd@sternir.com
